Karen Bush
About
In The Last Decade
Karen Bush
217 papers receiving 21.7k citations
Hit Papers
Peers
Comparison fields: 5 of 160
- Molecular Medicine 17.4k
- Pharmacology 7.3k
- Molecular Biology 5.8k
- Endocrinology 5.5k
- Epidemiology 4.3k
Countries citing papers authored by Karen Bush
This map shows the geographic impact of Karen Bush's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Bush with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Bush more than expected).
Fields of papers citing papers by Karen Bush
This network shows the impact of papers produced by Karen Bush. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Bush. The network helps show where Karen Bush may publish in the future.
Co-authorship network of co-authors of Karen Bush
This figure shows the co-authorship network connecting the top 25 collaborators of Karen Bush. A scholar is included among the top collaborators of Karen Bush based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Bush. Karen Bush is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | SAND: a comprehensive annotation of class D β-lactamases using structural alignment-based numbering | Antimicrobial Agents and Chemotherapy | James Spencer, Bogdan I. Iorga et al. | 2 |
| 2 | Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the | Arthritis Care & Research | Karen Bush, M. Elaine Husni et al. | 0 |
| 3 | Past, present, and future perspectives on aztreonam and avibactam | Expert Review of Anti-infective Therapy | Karen Bush | 3 |
| 4 | AB1122 GUSELKUMAB VS GOLIMUMAB IN PSA TNFI-INADEQUATE RESPONDERS (EVOLUTION): FORMULATING A PRAGMATIC PHASE 3B RANDOMIZED TRIAL | Annals of the Rheumatic Diseases | Soumya M. Reddy, Karen Bush et al. | 1 |
| 5 | Consensus on β-Lactamase Nomenclature | Antimicrobial Agents and Chemotherapy | Patricia A. Bradford, Robert A. Bonomo et al. | 16 |
| 6 | Critical analysis of antibacterial agents in clinical development breakdown → | Nature Reviews Microbiology | Ursula Theuretzbacher, Karen Bush et al. | 268 |
| 7 | Author Correction: Interplay between β-lactamases and new β-lactamase inhibitors | Nature Reviews Microbiology | Karen Bush, Patricia A. Bradford | 6 |
| 8 | Improving known classes of antibiotics: an optimistic approach for the future | Current Opinion in Pharmacology | Karen Bush | 81 |
| 9 | New antimicrobial agents on the horizon | Biochemical Pharmacology | Karen Bush, Michael J. Pucci | 43 |
| 10 | Introduction to Antimicrobial Therapeutics Reviews | Annals of the New York Academy of Sciences | Karen Bush | 2 |
| 11 | Extended-spectrum β-lactamases in North America, 1987–2006 | Clinical Microbiology and Infection | Karen Bush | 122 |
| 12 | A MurF Inhibitor That Disrupts Cell Wall Biosynthesis in Escherichia coli | Antimicrobial Agents and Chemotherapy | Ellen Z. Baum, Steven M. Crespo‐Carbone et al. | 37 |
| 13 | Amp C β-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge | Journal of Perinatology | Esra Fakioglu, Anne Marie Queenan et al. | 10 |
| 14 | First Nosocomial Outbreak of Pseudomonas aeruginosa Producing an Integron-Borne Metallo-β-Lactamase (VIM-2) in the United States | Antimicrobial Agents and Chemotherapy | Karen Lolans, Anne Marie Queenan et al. | 98 |
| 15 | Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase breakdown → | Nature Medicine | Ari Robicsek, Jacob Strahilevitz et al. | 750 |
| 16 | Taking inventory: antibacterial agents currently at or beyond Phase 1 | Current Opinion in Microbiology | Karen Bush, Mark J. Macielag et al. | 87 |
| 17 | Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones | Bioorganic & Medicinal Chemistry Letters | Barbara D. Foleno, Raúl Goldschmidt et al. | 37 |
| 18 | Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused byEscherichia coliandKlebsiella pneumoniaewith Reduced Susceptibility to Ceftazidime | Clinical Infectious Diseases | Annie Wong‐Beringer, Janet A. Hindler et al. | 110 |
| 19 | Antimicrobial agents | Current Opinion in Chemical Biology | Karen Bush | 25 |
| 20 | Izumenolide - a novel .BETA.-lactamase inhibitor produced by Micromonospora. II. Biological properties. | The Journal of Antibiotics | Karen Bush, D P Bonner et al. | 13 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.